AstraZeneca VP, Head of US Lung Cancer Franchise Discusses the Recent FDA Approval of TAGRISSO

In an interview with Pharm Exec Associate Editor Don Tracy, Arun Krishna, VP, Head of US Lung Cancer Franchise, AstraZeneca, talks about the FDA’s approval of TAGRISSO with the addition of chemotherapy in adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer.

Source link
#AstraZeneca #Lung #Cancer #Franchise #Discusses #FDA #Approval #TAGRISSO